Conversion From Fast Acting Oral Opioids to Abstral (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain

Trial Profile

Conversion From Fast Acting Oral Opioids to Abstral (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Orexo
  • Most Recent Events

    • 11 Aug 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-020239-38).
    • 19 Jun 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top